Improving the Identification and Management of Fibrosing Interstitial Lung Diseases Through the Power of the Multidisciplinary Care Team

This activity was originally presented live at Asembia's AXS26 Summit in Las Vegas, Nevada

Program Description

Fibrosing interstitial lung diseases (F-ILDs) encompasses progressive lung conditions including idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which are characterized by irreversible lung scarring, chronic cough, and high mortality rates. Currently, antifibrotic therapies are the primary strategy for treating ILDs, but these therapies are limited by their ability to slow disease progression rather than reverse existing lung scarring as well as high rates of adverse effects (AEs), particularly gastrointestinal and skin-related issues that contribute to suboptimal medication use and high discontinuation rates. Newer generation therapies offer potential improvements in both tolerability and novel mechanisms of action. As these new classes of medications move towards approval, pharmacists must understand their unique mechanisms of action to prepare for new monotherapy and combination therapy paradigms. This program will review the latest clinical evidence for the rapidly evolving F-ILD treatment landscape, preparing specialty pharmacists to integrate new therapies into existing workflows. Patient-centered cases emphasizing the value of the multidisciplinary care team will be presented to address the complexities of real-world treatment and management decisions for patients living with F-ILDs.

Target audience: Specialty pharmacists
Type of Activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate the pathophysiology and clinical burden of fibrosing interstitial lung diseases (F-ILDs) and idiopathic pulmonary fibrosis from progressive pulmonary fibrosis through updated diagnostic guidelines and recommended testing methods
• Examine currently approved antifibrotic therapies for F-ILD and their mechanisms of action, with attention to data on emerging therapeutic agents in the F-ILD pipeline and their potential impact on clinical care
• Provide activities and actions to use when working with the multidisciplinary team and the patient with an F-ILD by leveraging their consultation skills, sharing education with patients and their caregivers about their disease, and improving access to treatments that respect developments in clinical research, treatment guidelines, and emerging therapies.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-122-H01-P. The activity is available for CE credit through May 12, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Justin Oldham, MD, PhD, has the following relevant financial relationships with ineligible companies to disclose:

Grant/Research Support: Boehringer Ingelheim

Consultant: Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GSK, Insmed, Lupin, Mediar, Oorja Bio

Julie Galipean, PharmD, BCPS, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Vertex Pharmaceuticals Commercial Advisory Panel

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms